Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
7.93
+0.57 (7.74%)
At close: Aug 7, 2026, 4:00 PM EDT
7.98
+0.05 (0.63%)
Pre-market: Aug 10, 2026, 7:10 AM EDT
Xeris Biopharma Holdings Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, Xeris Biopharma Holdings stock has a consensus rating of "Strong Buy" and an average price target of $11.29. The average 1-year stock price forecast is 42.37% higher than the current stock price, while the lowest is $8.00 (+0.88%) and the highest is $18 (+126.99%).
Price Target: $11.29 (+42.37%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Xeris Biopharma Holdings stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
Unknown Analyst Oppenheimer No rating | Oppenheimer | Buy Reiterates $18 | Buy | Reiterates | $18 | +126.99% | Aug 7, 2026 |
| Piper Sandler | Piper Sandler | Hold Reiterates $8 | Hold | Reiterates | $8 | +0.88% | Aug 7, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $10 | Buy | Reiterates | $10 | +26.10% | Aug 7, 2026 |
| Craig-Hallum | Craig-Hallum | Buy Reiterates $12 | Buy | Reiterates | $12 | +51.32% | Jul 8, 2026 |
| Barclays | Barclays | Buy Reiterates $9 | Buy | Reiterates | $9 | +13.49% | May 14, 2026 |
Financial Forecast
Revenue This Year
387.49M
from 291.85M
Increased by 32.77%
Revenue Next Year
480.70M
from 387.49M
Increased by 24.06%
EPS This Year
-0.00
EPS Next Year
0.39
from -0.00
EPS and Forward PE are based on non-GAAP adjusted numbers.